IFI-M · CSK Tri-Axis Dominant-Primary Series

Specimen SS-F-M3-02230 // MULTI-AXIS · IFI-M

CSK Tri-Axis Dominant-Primary Series I-NP

Mentha × piperita

Peppermint

Tier ICSK Tri-Axis Dominant-Primary Series

Target Trait

1.1×

fold-change

Cooling-dominant tri-axis S+K modulated fold-change

Technical Specifications

SKU

SS-F-M3-02230

Genomic Edits

6

GC Content

44.8%

Construct Length

4,187 bp

Promoter System

Lipid nanoparticle / Ubiquitin

Expression System

Nanoparticle delivery

Host Strain

LNP-mediated

Receptor Target

TRPM8 + TAS1R2/TAS1R3 + CaSR

IFI Score

110

Pathway Edits

  • TRPM8 pathway primary gene cluster for cooling (IFI-C) tri-axis component
  • TAS1R2/TAS1R3 pathway primary gene cluster for sweet (IFI-S) tri-axis component
  • CaSR pathway primary gene cluster for kokumi (IFI-K) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent CSK pathway operation
  • Cross-pathway regulatory circuit for cooling-dominant CSK triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TRPM8, TAS1R2/TAS1R3, and CaSR pathways simultaneously engineeredCooling-dominant tri-axis expression strategy (CSK) with cross-pathway flux managementLNP-mediated delivery of triple-axis mRNA panel for transient expression profiling

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier I CSK triple-axis construct for advanced multi-modal sensory architecture combining cooling, sweet, and kokumi axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$549 · Tier I License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?

Back to Multi-Axis · IFI-MAll Modalities